|[May 19, 2014]
Research and Markets: Safinamide (Parkinson's Disease) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/76x5rk/safinamide)
has announced the addition of the "Safinamide
(Parkinson's Disease) - Forecast and Market Analysis to 2022"
report to their offering.
In 2012, Newron completed Phase III clinical trials for safinamide, a
dual-mechanism a-aminoamide derivative, acting as an MAO-B and glutamate
release inhibitor (EPDA, press release, May 14, 2012). In 2006, Merck
Serono (a division of Merck KGaA) had acquied the exclusive worldwide
rights for safinamide; however, in 2011 the deal was terminated, seeing
Merck returning the compound to Newron due to concerns over the
potential market size for the drug.
Overview of Parkinson's disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on Safinamide including product description,
safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Safinamide for the top seven countries from 2012 to
Sales information covered for the US, France, Germany, Italy, Spain,
the UK and Brazil.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/76x5rk/safinamide
[ Back To TMCnet.com's Homepage ]